MedWatch

Demant recalls cochlear implants – will cost up to EUR 13.4m in 2021, with more consequences for 2022

Oticon Medical, the surgical division of hearing aid group Demant, has located a performance issue in a number of non-implanted Neuro Zti cochlear implants, and the company sees no other option than to immediately withdraw the product from the market.

Photo: Demant / PR

Bad things often happen in threes, and they just keep coming for hearing aid manufacturer Demant. First, the company was hit by a cyber attack which effectively shut down the company for weeks, then the pandemic hit, and now Oticon Medical, the sugical division at Demant, is experiencing headwind.

On Thursday, Demant reports that its surgical branch has identified serious performance issues in 28 implanted devices. As a consequence, Oticon Medical is recalling around 4000 non-implanted Neuro Zti devices.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs